thyroxine has been researched along with Developmental Disabilities in 69 studies
Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.
thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.
Developmental Disabilities: Disorders in which there is a delay in development based on that expected for a given age level or stage of development. These impairments or disabilities originate before age 18, may be expected to continue indefinitely, and constitute a substantial impairment. Biological and nonbiological factors are involved in these disorders. (From American Psychiatric Glossary, 6th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " It is unknown whether levothyroxine treatment of women who are identified as having subclinical hypothyroidism or hypothyroxinemia during pregnancy improves cognitive function in their children." | 9.24 | Treatment of Subclinical Hypothyroidism or Hypothyroxinemia in Pregnancy. ( Caritis, SN; Casey, BM; Hirtz, DG; Iams, JD; Mercer, BM; Peaceman, AM; Reddy, UM; Rouse, DJ; Saade, G; Sibai, B; Sorokin, Y; Thom, EA; Thorp, JM; Tita, AT; Tolosa, J; VanDorsten, JP; Varner, MW; Wapner, RJ, 2017) |
| "Low free thyroxine levels (<5th percentile) and self-reported prepregnancy thyroid disorder without medical treatment were associated with a decrease of mental scores (Beta = -3." | 7.79 | Thyroxine levels during pregnancy in healthy women and early child neurodevelopment. ( Alvarez-Pedrerol, M; Espada, M; Forns, J; Garcia-Esteban, R; Julvez, J; Lertxundi, N; Murcia, M; Rebagliato, M; Riaño Galán, I; Sunyer, J; Tardón, A, 2013) |
| "We sought to examine the neurobehavioral profile of neonates who are born to women with hypothyroxinemia during early pregnancy." | 7.73 | Neonatal effects of maternal hypothyroxinemia during early pregnancy. ( Brouwers, EP; Crawford, S; Kooistra, L; Pop, VJ; van Baar, AL, 2006) |
| " It is unknown whether levothyroxine treatment of women who are identified as having subclinical hypothyroidism or hypothyroxinemia during pregnancy improves cognitive function in their children." | 5.24 | Treatment of Subclinical Hypothyroidism or Hypothyroxinemia in Pregnancy. ( Caritis, SN; Casey, BM; Hirtz, DG; Iams, JD; Mercer, BM; Peaceman, AM; Reddy, UM; Rouse, DJ; Saade, G; Sibai, B; Sorokin, Y; Thom, EA; Thorp, JM; Tita, AT; Tolosa, J; VanDorsten, JP; Varner, MW; Wapner, RJ, 2017) |
| "To compare neurodevelopmental outcomes in severe and moderate congenital hypothyroidism (CH) among 3 different initial L-thyroxine doses and to examine the effect of the time to thyroid function normalization on neurodevelopmental outcomes." | 5.11 | Neurodevelopmental outcomes in congenital hypothyroidism: comparison of initial T4 dose and time to reach target T4 and TSH. ( Blasco, PA; Downs, A; Harper, A; Lafranchi, SH; Selva, KA, 2005) |
| " Observational studies suggest that children whose mothers had hypothyroxinemia in early pregnancy have lower IQs than matched controls." | 4.82 | Hypothyroidism during pregnancy. ( Koren, G; Nava-Ocampo, AA; Soldin, OP, 2004) |
| "Cretinism, which is characterized by marked intellectual impairment and is associated with severe iodine deficiency, has been appreciated for many years." | 4.80 | Thyroid hormone and intellectual development: a clinician's view. ( Lazarus, JH, 1999) |
| " Firstly, in infants with a defect of glandular ontogenesis (congenital hypothyroidism), the participation of maternal thyroid hormones to the fetal circulating thyroxine environment is normal and, therefore, risk of brain damage results exclusively from the insufficient hormone production by the abnormal fetal thyroid gland." | 4.80 | The potential repercussions of maternal, fetal, and neonatal hypothyroxinemia on the progeny. ( Delange, F; Glinoer, D, 2000) |
| "Low free thyroxine levels (<5th percentile) and self-reported prepregnancy thyroid disorder without medical treatment were associated with a decrease of mental scores (Beta = -3." | 3.79 | Thyroxine levels during pregnancy in healthy women and early child neurodevelopment. ( Alvarez-Pedrerol, M; Espada, M; Forns, J; Garcia-Esteban, R; Julvez, J; Lertxundi, N; Murcia, M; Rebagliato, M; Riaño Galán, I; Sunyer, J; Tardón, A, 2013) |
| "After 12 weeks of treatment (before pregnancy), iodine concentrations in urine and thyroid tissue and circulating thyroxine of adult females correlated with iodine intake." | 3.78 | Effect of maternal excessive iodine intake on neurodevelopment and cognitive function in rat offspring. ( Fan, C; Li, J; Liu, Y; Mao, J; Shan, Z; Teng, W; Wang, H; Zhang, H; Zhang, L, 2012) |
| " This case emphasizes the importance of screening for hypothyroidism in patients with hemangiomas and the potential therapeutic benefit of prednisolone therapy in this condition." | 3.74 | Case report: consumptive hypothyroidism consequent to multiple infantile hepatic haemangiomas. ( Cho, YH; Hardwick, R; Howard, NJ; Howman-Giles, R; Lord, D; Mansour, A; Taplin, C, 2008) |
| "We sought to examine the neurobehavioral profile of neonates who are born to women with hypothyroxinemia during early pregnancy." | 3.73 | Neonatal effects of maternal hypothyroxinemia during early pregnancy. ( Brouwers, EP; Crawford, S; Kooistra, L; Pop, VJ; van Baar, AL, 2006) |
| "The purpose of this study was to determine whether children with borderline hypothyroidism in the neonatal period had persistent hypothyroidism after 3 years of levothyroxine replacement therapy." | 3.70 | Three-year follow-up of borderline congenital hypothyroidism. ( Daliva, AL; DiMartino-Nardi, J; Linder, B; Saenger, P, 2000) |
| " In both populations correlations were found between some results and two factors related to hypothyroidism: delayed bone surface development and thyroxinemia at the time of diagnosis." | 3.68 | [Comparative study of psychometric results of 2 french speaking populations with hypothyroidism detected at birth]. ( Dussault, J; Farriaux, JP; Glorieux, J; Lebecq, MF; Morissette, J, 1990) |
| "Subclinical hypothyroidism has been found to be associated with adverse reproductive outcomes, such as infertility, miscarriage, preterm birth, and complications of pregnancy." | 2.53 | The Impact and Management of Subclinical Hypothyroidism for Improving Reproductive Outcomes such as Fertility and Miscarriage. ( Seungdamrong, A, 2016) |
| "We report a Fryns Anophthalmia-Plus Syndrome in a child with unusual findings including central hypothyroidism, chiari type 2 malformation, conductive hearing loss and developmental regression." | 2.49 | Anophthalmia-plus syndrome with unusual findings. A clinical report and review of the literature. ( Cayir, A; Eroz, R; Orbak, Z; Tasdemir, S; Tatar, A; Yuce, I, 2013) |
| "Acquired primary hypothyroidism in infancy can be related to autoimmune thyroiditis and can present with unusual symptoms, such as muscle pseudohypertrophy and pituitary tumor." | 1.34 | Unusual clinical presentation of primary hypothyroidism in a very young infant caused by autoimmune thyroiditis: case report and update of the literature. ( Bettendorf, M; Ebinger, F; Mittnacht, J; Schmidt, F, 2007) |
| "Acquired hypothyroidism is rare before age 3 years, and rhabdomyolysis due to hypothyroidism has not previously been reported as a cause of delayed gross-motor development in toddlerhood." | 1.33 | Onset of acquired autoimmune hypothyroidism in infancy: a presentation of delayed gross-motor development and rhabdomyolysis. ( Chiu, HK; Gunther, DF; Kletter, GB; Numrych, TE, 2006) |
| "The frequency of SH in children with neurological disorders was of 7." | 1.32 | [Frequency of subclinical hypothyroidism among healthy children and those with neurological conditions in the state of Mérida, Venezuela]. ( Arata-Bellabarba, G; Arias-Ferreira, A; Bianchi, G; Jiménez-López, V; Mamán-Alvarado, D; Paoli-Valeri, M, 2003) |
| "The hypothyroidism is a frequent endocrinopathos." | 1.31 | [Hypothyroidism in children. 82 cases]. ( Ben Amar, H; Ben Slimen, M; Hachicha, M; Kolsi, S; Loulou, F; Mahfoudh, A; Rekik, S; Triki, A, 2002) |
| " the most severe vs other types), the initial low serum T4 levels (< or = 53 nmol/L vs >53 nmol/L), and the profound bone maturation delay (absence vs presence of the two knee epiphyseal ossification centres at diagnosis), initially low L-thyroxine dosage (below vs > or = 7 microg/kg/day), the absence of near normalization of thyroid hormone levels after 15 d of treatment and poor adequacy of treatment throughout childhood were associated with an increased risk of school delay." | 1.31 | Influence of severity of congenital hypothyroidism and adequacy of treatment on school achievement in young adolescents: a population-based cohort study. ( Larroque, B; Léger, J; Norton, J, 2001) |
| "With the diagnosis of neonatal Graves' disease established, both twins were treated with propranolol (2 mg/kg." | 1.30 | [Neonatal Basedow's disease in twins from a mother with severe T3 hyperthyroidism]. ( Grüters, A; Hüfner, M; Lakomek, M; Roth, C; Siggelkow, H, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (4.35) | 18.7374 |
| 1990's | 15 (21.74) | 18.2507 |
| 2000's | 35 (50.72) | 29.6817 |
| 2010's | 14 (20.29) | 24.3611 |
| 2020's | 2 (2.90) | 2.80 |
| Authors | Studies |
|---|---|
| Goel, D | 1 |
| Luig, M | 1 |
| Maheshwari, R | 1 |
| D'Cruz, D | 1 |
| Goyen, TA | 1 |
| Erbaş, İM | 1 |
| Demir, K | 1 |
| Cayir, A | 1 |
| Tasdemir, S | 1 |
| Eroz, R | 1 |
| Yuce, I | 1 |
| Orbak, Z | 1 |
| Tatar, A | 1 |
| Cuestas, E | 1 |
| Gaido, MI | 1 |
| Capra, RH | 1 |
| Hollanders, JJ | 1 |
| Israëls, J | 1 |
| van der Pal, SM | 1 |
| Verkerk, PH | 1 |
| Rotteveel, J | 1 |
| Finken, MJ | 1 |
| Balogun, FM | 1 |
| Jarrett, OO | 1 |
| Seungdamrong, A | 1 |
| Casey, BM | 1 |
| Thom, EA | 1 |
| Peaceman, AM | 1 |
| Varner, MW | 1 |
| Sorokin, Y | 1 |
| Hirtz, DG | 1 |
| Reddy, UM | 1 |
| Wapner, RJ | 1 |
| Thorp, JM | 1 |
| Saade, G | 1 |
| Tita, AT | 1 |
| Rouse, DJ | 1 |
| Sibai, B | 1 |
| Iams, JD | 1 |
| Mercer, BM | 1 |
| Tolosa, J | 1 |
| Caritis, SN | 1 |
| VanDorsten, JP | 1 |
| Ng, SM | 1 |
| Turner, MA | 1 |
| Gamble, C | 1 |
| Didi, M | 1 |
| Victor, S | 1 |
| Malamateniou, C | 1 |
| Parkes, LM | 1 |
| Tietze, A | 1 |
| Gregory, L | 1 |
| Sluming, V | 1 |
| Abernethy, L | 1 |
| Weindling, AM | 1 |
| Williams, FL | 1 |
| Hume, R | 3 |
| Blumenfeld, Z | 1 |
| Simic, N | 1 |
| Asztalos, EV | 1 |
| Rovet, J | 1 |
| Moleti, M | 1 |
| Vermiglio, F | 1 |
| Trimarchi, F | 1 |
| Berbel, P | 1 |
| Navarro, D | 1 |
| Ausó, E | 1 |
| Varea, E | 1 |
| Rodríguez, AE | 1 |
| Ballesta, JJ | 1 |
| Salinas, M | 1 |
| Flores, E | 1 |
| Faura, CC | 1 |
| de Escobar, GM | 1 |
| Joseph, R | 1 |
| Linn, M | 1 |
| Yoder, BA | 1 |
| Clark, RH | 1 |
| Delahunty, C | 1 |
| Falconer, S | 1 |
| Jackson, L | 1 |
| Midgley, P | 1 |
| Mirfield, M | 1 |
| Ogston, S | 1 |
| Perra, O | 1 |
| Simpson, J | 1 |
| Watson, J | 1 |
| Willatts, P | 1 |
| Williams, F | 1 |
| Huo, K | 1 |
| Zhang, Z | 1 |
| Zhao, D | 1 |
| Li, H | 1 |
| Wang, J | 1 |
| Wang, X | 2 |
| Feng, H | 1 |
| Zhu, C | 1 |
| La Gamma, EF | 1 |
| Paneth, N | 2 |
| Momotani, N | 1 |
| Iwama, S | 1 |
| Momotani, K | 1 |
| Zhang, L | 1 |
| Teng, W | 1 |
| Liu, Y | 1 |
| Li, J | 1 |
| Mao, J | 1 |
| Fan, C | 1 |
| Wang, H | 1 |
| Zhang, H | 1 |
| Shan, Z | 1 |
| Julvez, J | 1 |
| Alvarez-Pedrerol, M | 1 |
| Rebagliato, M | 1 |
| Murcia, M | 1 |
| Forns, J | 1 |
| Garcia-Esteban, R | 1 |
| Lertxundi, N | 1 |
| Espada, M | 1 |
| Tardón, A | 1 |
| Riaño Galán, I | 1 |
| Sunyer, J | 1 |
| Beltroy, E | 1 |
| Umpaichitra, V | 1 |
| Gordon, S | 1 |
| Castells, S | 1 |
| O'Connor, K | 1 |
| Gomez, R | 1 |
| Knoebel, E | 1 |
| Hachicha, M | 1 |
| Mahfoudh, A | 1 |
| Loulou, F | 1 |
| Ben Amar, H | 1 |
| Kolsi, S | 1 |
| Ben Slimen, M | 1 |
| Rekik, S | 1 |
| Triki, A | 1 |
| Paoli-Valeri, M | 1 |
| Mamán-Alvarado, D | 1 |
| Jiménez-López, V | 1 |
| Arias-Ferreira, A | 1 |
| Bianchi, G | 1 |
| Arata-Bellabarba, G | 1 |
| Nava-Ocampo, AA | 1 |
| Soldin, OP | 1 |
| Koren, G | 1 |
| Rovet, JF | 1 |
| Simoneau-Roy, J | 1 |
| Marti, S | 1 |
| Deal, C | 1 |
| Huot, C | 1 |
| Robaey, P | 1 |
| Van Vliet, G | 2 |
| Joergensen, JV | 1 |
| Oerbeck, B | 1 |
| Jebsen, P | 1 |
| Heyerdahl, S | 2 |
| Kase, BF | 1 |
| van Wassenaer, AG | 4 |
| Westera, J | 1 |
| Houtzager, BA | 1 |
| Kok, JH | 4 |
| Bongers-Schokking, JJ | 1 |
| de Muinck Keizer-Schrama, SM | 1 |
| Selva, KA | 1 |
| Harper, A | 1 |
| Downs, A | 1 |
| Blasco, PA | 1 |
| Lafranchi, SH | 1 |
| Kooistra, L | 1 |
| Crawford, S | 1 |
| van Baar, AL | 3 |
| Brouwers, EP | 1 |
| Pop, VJ | 2 |
| Gunther, DF | 1 |
| Chiu, HK | 1 |
| Numrych, TE | 1 |
| Kletter, GB | 1 |
| Pniewska-Siark, B | 1 |
| Jeziorowska, A | 1 |
| Bobeff, I | 1 |
| Lewiński, A | 1 |
| Mittnacht, J | 1 |
| Schmidt, F | 1 |
| Ebinger, F | 1 |
| Bettendorf, M | 1 |
| Osborn, DA | 3 |
| Hunt, RW | 1 |
| Tajima, T | 1 |
| Fujiwara, F | 1 |
| Sudo, A | 1 |
| Saito, S | 1 |
| Fujieda, K | 1 |
| Cho, YH | 1 |
| Taplin, C | 1 |
| Mansour, A | 1 |
| Howman-Giles, R | 1 |
| Hardwick, R | 1 |
| Lord, D | 1 |
| Howard, NJ | 1 |
| Winkler, L | 1 |
| Bank, S | 1 |
| Bremer-Hübler, U | 1 |
| Brodehl, J | 1 |
| Sander, J | 1 |
| Simons, WF | 1 |
| Fuggle, PW | 1 |
| Grant, DB | 1 |
| Smith, I | 1 |
| de Vijlder, JJ | 3 |
| Briët, JM | 3 |
| Smit, BJ | 1 |
| Tamminga, P | 1 |
| van Baar, A | 2 |
| Dekker, FW | 2 |
| Vulsma, T | 2 |
| Roth, C | 1 |
| Siggelkow, H | 1 |
| Grüters, A | 1 |
| Hüfner, M | 1 |
| Lakomek, M | 1 |
| Lazarus, JH | 2 |
| Haddow, JE | 1 |
| Palomaki, GE | 1 |
| Allan, WC | 1 |
| Williams, JR | 1 |
| Knight, GJ | 1 |
| Gagnon, J | 1 |
| O'Heir, CE | 1 |
| Mitchell, ML | 2 |
| Hermos, RJ | 1 |
| Waisbren, SE | 1 |
| Faix, JD | 1 |
| Klein, RZ | 2 |
| Morreale de Escobar, G | 2 |
| Escobar del Rey, F | 2 |
| Rapaport, R | 1 |
| Daliva, AL | 1 |
| Linder, B | 1 |
| DiMartino-Nardi, J | 1 |
| Saenger, P | 1 |
| Kokandi, A | 1 |
| Glinoer, D | 1 |
| Delange, F | 1 |
| Obregón, MJ | 1 |
| Léger, J | 1 |
| Larroque, B | 1 |
| Norton, J | 1 |
| Meijer, WJ | 1 |
| Verloove-Vanhorick, SP | 1 |
| Brand, R | 1 |
| van den Brande, JL | 1 |
| Toublanc, JE | 1 |
| Rives, S | 1 |
| Acosta, A | 1 |
| Chicaud, J | 1 |
| Lebecq, MF | 1 |
| Glorieux, J | 1 |
| Farriaux, JP | 1 |
| Dussault, J | 1 |
| Morissette, J | 1 |
| Ranke, MB | 1 |
| Bierich, JR | 1 |
| Kozlowski, BW | 1 |
| Taylor, ML | 1 |
| Baer, MT | 1 |
| Blyler, EM | 1 |
| Trahms, C | 1 |
| Tan, SH | 1 |
| Wong, HB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial of Thyroxine Therapy for Subclinical Hypothyroidism or Hypothyroxinemia Diagnosed During Pregnancy[NCT00388297] | Phase 3 | 1,203 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Transient Hypothyroxinemia of Prematurity: Electrophysiological Changes in the Preterm Infants' Brain, a Retrospective Study[NCT03493113] | 87 participants (Actual) | Observational | 2011-10-31 | Completed | |||
| Are IQs Low in Offspring of Euthyroid Women With Low T4?[NCT00147433] | 5,000 participants | Observational | 2004-02-29 | Recruiting | |||
| Evaluation of Thyroid Function in Children With Congenital Heart Disease[NCT03496363] | 50 participants (Anticipated) | Observational | 2018-05-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Conners' Rating Scales-Revised were used to assess attention deficit-hyperactivity disorder (ADHD). A T score of 45 to 55 is considered to be typical or average; a T score of 44 or less is not a concern, a T score of 56 to 60 is considered to be a borderline score, and a T score of 61 or higher indicates a possible or clinically significant problem. (NCT00388297)
Timeframe: 48 months of age
| Intervention | T-score (Median) |
|---|---|
| Levothyroxine for Subclinical Hypothyroidism | 48 |
| Placebo for Levothyroxine - Subclinical Hypothyroidism | 49 |
| Levothyroxine for Hypothyroxinemia | 50 |
| Placebo for Levothyroxine - Hypothyroxinemia | 49 |
"Overall general conceptual ability score as measured by the DAS-II at 36 months of age.~GCA General Conceptual Ability Classification ≥ 130 Very high 120-129 High 110-119 Above average 90-109 Average 80-89 Below average 70-79 Low~≤ 69 Very low" (NCT00388297)
Timeframe: 36 months
| Intervention | score on a scale (Median) |
|---|---|
| Levothyroxine for Subclinical Hypothyroidism | 90 |
| Placebo for Levothyroxine - Subclinical Hypothyroidism | 90 |
| Levothyroxine for Hypothyroxinemia | 90 |
| Placebo for Levothyroxine - Hypothyroxinemia | 89 |
A patient is considered to have gestational diabetes if clinically diagnosed with class A1 or A2 (NCT00388297)
Timeframe: During pregnancy until delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Levothyroxine for Subclinical Hypothyroidism | 25 |
| Placebo for Levothyroxine - Subclinical Hypothyroidism | 22 |
| Levothyroxine for Hypothyroxinemia | 21 |
| Placebo for Levothyroxine - Hypothyroxinemia | 24 |
Birth weight < 10th percentile (gestational age z score) (NCT00388297)
Timeframe: Delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Levothyroxine for Subclinical Hypothyroidism | 33 |
| Placebo for Levothyroxine - Subclinical Hypothyroidism | 27 |
| Levothyroxine for Hypothyroxinemia | 23 |
| Placebo for Levothyroxine - Hypothyroxinemia | 20 |
"The primary outcome was death or IQ score at 5 years of age (or at 3 years of age if the 5-year examination was missing). The full-scale IQ was assessed with the use of the Wechsler Preschool and Primary Scale of Intelligence III (WPPSI-III) at 5 years of age or the overall (general conceptual ability) score from the Differential Ability Scales-II at 3 years of age if the WPPSI-III score was not available. Results are expressed as an age-standardized score, with an expected population mean of 100 and a standard deviation of 15. Death before 3 years of age was assigned a score of 0 (lowest possible rank) and was included in the estimation of the median.~For Quotient and Composite score:~below 70 is Extremely Low, 70-79 is Borderline, 80-89 is Low Average, 90-109 is Average, 110-119 is High Average, 120-129 is Superior, 130+" (NCT00388297)
Timeframe: 60 months of age
| Intervention | score on a scale (Median) |
|---|---|
| Levothyroxine for Subclinical Hypothyroidism | 97 |
| Placebo for Levothyroxine - Subclinical Hypothyroidism | 94 |
| Levothyroxine for Hypothyroxinemia | 94 |
| Placebo for Levothyroxine - Hypothyroxinemia | 91 |
Neonatal head circumference measured within 24 hours of birth. This measurement is included based on a report showing that maternal treatment with thyroxine for overt hypothyroidism was associated with reduced head circumference in the newborn infant (NCT00388297)
Timeframe: Within 24 hours of birth
| Intervention | centimeters (Mean) |
|---|---|
| Levothyroxine for Subclinical Hypothyroidism | 33.9 |
| Placebo for Levothyroxine - Subclinical Hypothyroidism | 33.9 |
| Levothyroxine for Hypothyroxinemia | 33.9 |
| Placebo for Levothyroxine - Hypothyroxinemia | 34.2 |
Median number of days in the hospital nursery (NCT00388297)
Timeframe: Through hospital discharge
| Intervention | days (Median) |
|---|---|
| Levothyroxine for Subclinical Hypothyroidism | 2 |
| Placebo for Levothyroxine - Subclinical Hypothyroidism | 2 |
| Levothyroxine for Hypothyroxinemia | 2 |
| Placebo for Levothyroxine - Hypothyroxinemia | 2 |
Admission to NICU (NCT00388297)
Timeframe: Delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Levothyroxine for Subclinical Hypothyroidism | 29 |
| Placebo for Levothyroxine - Subclinical Hypothyroidism | 21 |
| Levothyroxine for Hypothyroxinemia | 31 |
| Placebo for Levothyroxine - Hypothyroxinemia | 31 |
Bronchopulmonary dysplasia (BPD) is defined as the need for supplemental oxygen at 36 weeks corrected age, for babies born <34 weeks by project gestational age only (NCT00388297)
Timeframe: Through 72 hours post delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Levothyroxine for Subclinical Hypothyroidism | 0 |
| Placebo for Levothyroxine - Subclinical Hypothyroidism | 1 |
| Levothyroxine for Hypothyroxinemia | 0 |
| Placebo for Levothyroxine - Hypothyroxinemia | 1 |
Necrotizing enterocolitis (NEC) is defined by the following: the unequivocal presence of intramural air on abdominal x-ray, perforation seen on abdominal x-ray, clinical evidence as suggested by erythema and induration of the abdominal wall, or intra-abdominal abscess formation, or stricture formation observed at surgery or autopsy following an episode of suspected NEC. The condition is classified based on the Bell staging system (NCT00388297)
Timeframe: Delivery within 2 weeks of birth
| Intervention | Participants (Count of Participants) |
|---|---|
| Levothyroxine for Subclinical Hypothyroidism | 1 |
| Placebo for Levothyroxine - Subclinical Hypothyroidism | 1 |
| Levothyroxine for Hypothyroxinemia | 2 |
| Placebo for Levothyroxine - Hypothyroxinemia | 0 |
Respiratory distress syndrome (RDS) will be defined based on a clinical diagnosis of RDS Type I and oxygen therapy (FiO2 ≥ 0.40) for greater than or equal to 24 hours. For infants dying before 24 hours of age, a clinical diagnosis of RDS Type I and oxygen therapy (FiO2 ≥ 0.40) are sufficient. (NCT00388297)
Timeframe: Delivery and greater than or equal to 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Levothyroxine for Subclinical Hypothyroidism | 9 |
| Placebo for Levothyroxine - Subclinical Hypothyroidism | 6 |
| Levothyroxine for Hypothyroxinemia | 4 |
| Placebo for Levothyroxine - Hypothyroxinemia | 5 |
oxygen therapy (FiO2 ≥ 0.40) for greater than or equal to 24 hours (NCT00388297)
Timeframe: 72 hours post delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Levothyroxine for Subclinical Hypothyroidism | 11 |
| Placebo for Levothyroxine - Subclinical Hypothyroidism | 11 |
| Levothyroxine for Hypothyroxinemia | 13 |
| Placebo for Levothyroxine - Hypothyroxinemia | 12 |
This diagnosis will be reached when an ophthalmologic examination of the retina has been performed and ROP is diagnosed at Stage I (demarcation line in the retina) or greater (NCT00388297)
Timeframe: Through 72 hours of birth
| Intervention | Participants (Count of Participants) |
|---|---|
| Levothyroxine for Subclinical Hypothyroidism | 1 |
| Placebo for Levothyroxine - Subclinical Hypothyroidism | 0 |
| Levothyroxine for Hypothyroxinemia | 0 |
| Placebo for Levothyroxine - Hypothyroxinemia | 0 |
Fetal and neonatal death (NCT00388297)
Timeframe: Through 72 hours post delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Levothyroxine for Subclinical Hypothyroidism | 0 |
| Placebo for Levothyroxine - Subclinical Hypothyroidism | 1 |
| Levothyroxine for Hypothyroxinemia | 1 |
| Placebo for Levothyroxine - Hypothyroxinemia | 1 |
Stillbirth or miscarriage. (NCT00388297)
Timeframe: Delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Levothyroxine for Subclinical Hypothyroidism | 4 |
| Placebo for Levothyroxine - Subclinical Hypothyroidism | 7 |
| Levothyroxine for Hypothyroxinemia | 2 |
| Placebo for Levothyroxine - Hypothyroxinemia | 5 |
The composite neonatal outcome was defined as periventricular leukomalacia, intraventricular hemorrhage of grade III or IV, necrotizing enterocolitis (stage ≥II), severe retinopathy of prematurity (stage ≥III), the severe respiratory distress syndrome, bronchopulmonary dysplasia, neonatal death, stillbirth, or serious infectious complication. (NCT00388297)
Timeframe: Within 72 hours of delivery.
| Intervention | Participants (Count of Participants) |
|---|---|
| Levothyroxine for Subclinical Hypothyroidism | 7 |
| Placebo for Levothyroxine - Subclinical Hypothyroidism | 12 |
| Levothyroxine for Hypothyroxinemia | 5 |
| Placebo for Levothyroxine - Hypothyroxinemia | 7 |
Gestational hypertension defined as patient having a diastolic ≥ 90 during pregnancy without proteinuria (NCT00388297)
Timeframe: During pregnancy and until delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Levothyroxine for Subclinical Hypothyroidism | 33 |
| Placebo for Levothyroxine - Subclinical Hypothyroidism | 36 |
| Levothyroxine for Hypothyroxinemia | 20 |
| Placebo for Levothyroxine - Hypothyroxinemia | 24 |
Clinically significant placental abruption will be determined by centralized (blinded) chart review (NCT00388297)
Timeframe: Duration of pregnancy, delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Levothyroxine for Subclinical Hypothyroidism | 1 |
| Placebo for Levothyroxine - Subclinical Hypothyroidism | 5 |
| Levothyroxine for Hypothyroxinemia | 3 |
| Placebo for Levothyroxine - Hypothyroxinemia | 2 |
Preeclampsia defined as patient having a diastolic ≥ 90 during pregnancy with at least 1 + proteinuria. Preeclampsia will also include HELLP syndrome or eclampsia. (NCT00388297)
Timeframe: Duration of pregnancy, Delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Levothyroxine for Subclinical Hypothyroidism | 22 |
| Placebo for Levothyroxine - Subclinical Hypothyroidism | 20 |
| Levothyroxine for Hypothyroxinemia | 9 |
| Placebo for Levothyroxine - Hypothyroxinemia | 11 |
"Standardized full-scale IQ scores from the Wechsler Preschool and Primary Scale of Intelligence III (WPPSI-III) at 5 years of age. Quotient and Composite scores have a mean of 100 and a standard deviation of 15. Subtest scaled scores have a mean of 10 and a standard deviation of 3.~For Quotient and Composite score:~below 70 is Extremely Low, 70-79 is Borderline, 80-89 is Low Average, 90-109 is Average, 110-119 is High Average, 120-129 is Superior, 130+ is Very Superior." (NCT00388297)
Timeframe: 60 months
| Intervention | score on a scale (Median) |
|---|---|
| Levothyroxine for Subclinical Hypothyroidism | 97 |
| Placebo for Levothyroxine - Subclinical Hypothyroidism | 95 |
| Levothyroxine for Hypothyroxinemia | 94 |
| Placebo for Levothyroxine - Hypothyroxinemia | 92 |
Gestational age at delivery and preterm birth < 37 weeks' gestation or < 34 weeks' gestation (NCT00388297)
Timeframe: Delivery
| Intervention | weeks (Mean) |
|---|---|
| Levothyroxine for Subclinical Hypothyroidism | 39.1 |
| Placebo for Levothyroxine - Subclinical Hypothyroidism | 38.9 |
| Levothyroxine for Hypothyroxinemia | 39.0 |
| Placebo for Levothyroxine - Hypothyroxinemia | 38.8 |
Behavioral problems and social competencies at 36 and 60 months of age, as measured by the Child Behavior Checklist (CBCL). The CBCL is filled out by the caregiver. Each of the 100 questions indicates a behavior for which the caregiver scores as Not True (0), Sometimes True (1), or Often True (2). The scores for all the questions are then summed and evaluated against the normative data/T-scores. A Tscore of less than 60 is considered to be in the normal range. A T score of 60-63 is a borderline, and a T score of more than 63 is in the clinical range. Lower scores represent better outcomes. (NCT00388297)
Timeframe: 36 and 60 months of age
| Intervention | T-score (Median) | |
|---|---|---|
| CBCL T score at 36 mo | CBCL T score at 60 mo | |
| Levothyroxine for Hypothyroxinemia | 48 | 45 |
| Levothyroxine for Subclinical Hypothyroidism | 46 | 44 |
| Placebo for Levothyroxine - Hypothyroxinemia | 48 | 43 |
| Placebo for Levothyroxine - Subclinical Hypothyroidism | 46 | 44 |
"Cognitive and achievement levels from two DAS-II subtests (Recall of Digits Forward and Recognition of Pictures)~GCA General Conceptual Ability Classification ≥ 130 Very high 120-129 High 110-119 Above average 90-109 Average 80-89 Below average 70-79 Low~≤ 69 Very low" (NCT00388297)
Timeframe: 48 months of age
| Intervention | score on a scale (Median) | |
|---|---|---|
| Median Recall of Digits Forward Score | Median Recognition of Pictures Score | |
| Levothyroxine for Hypothyroxinemia | 91 | 84 |
| Levothyroxine for Subclinical Hypothyroidism | 84 | 74 |
| Placebo for Levothyroxine - Hypothyroxinemia | 74 | 74 |
| Placebo for Levothyroxine - Subclinical Hypothyroidism | 84 | 74 |
Composite scores are derived for cognitive, language, and motor development and scaled to a metric, with a mean of 100, standard deviation of 15, and range of 40 to 160. Results can also be expressed as percentile ranks relative to the standardization sample, with a mean and median of 50 and range from 1 to 99 (NCT00388297)
Timeframe: 12 and 24 months of age
| Intervention | score on a scale (Median) | |||||
|---|---|---|---|---|---|---|
| Median 12 mo cognitive score | Median 12 mo motor score | Median 12 mo language score | Median 24 mo cognitive score | Median 24 mo motor score | Median 24 mo language score | |
| Levothyroxine for Hypothyroxinemia | 100 | 97 | 94 | 90 | 97 | 89 |
| Levothyroxine for Subclinical Hypothyroidism | 100 | 97 | 94 | 90 | 97 | 89 |
| Placebo for Levothyroxine - Hypothyroxinemia | 100 | 97 | 94 | 90 | 97 | 89 |
| Placebo for Levothyroxine - Subclinical Hypothyroidism | 100 | 97 | 94 | 90 | 97 | 91 |
Apgar score < 4 at 1 minute and < 7 at 5 minutes (NCT00388297)
Timeframe: 1 minute and 5 minutes post delivery
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Apgar < 4 at 1 minute | Apgar < 7 at 5 minutes | |
| Levothyroxine for Hypothyroxinemia | 6 | 2 |
| Levothyroxine for Subclinical Hypothyroidism | 6 | 2 |
| Placebo for Levothyroxine - Hypothyroxinemia | 7 | 4 |
| Placebo for Levothyroxine - Subclinical Hypothyroidism | 7 | 3 |
Preterm delivery at less than 37 weeks or less than 34 weeks gestation (NCT00388297)
Timeframe: Delivery
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Preterm birth < 34 wk | Preterm birth < 37 wk | |
| Levothyroxine for Hypothyroxinemia | 10 | 31 |
| Levothyroxine for Subclinical Hypothyroidism | 9 | 31 |
| Placebo for Levothyroxine - Hypothyroxinemia | 7 | 20 |
| Placebo for Levothyroxine - Subclinical Hypothyroidism | 10 | 37 |
19 reviews available for thyroxine and Developmental Disabilities
| Article | Year |
|---|---|
The Clinical Spectrum of Resistance to Thyroid Hormone Alpha in Children and Adults
Topics: Adult; Autism Spectrum Disorder; Child; Constipation; Developmental Disabilities; Growth Disorders; | 2021 |
Anophthalmia-plus syndrome with unusual findings. A clinical report and review of the literature.
Topics: Abnormalities, Multiple; Anophthalmos; Arnold-Chiari Malformation; Child, Preschool; Developmental D | 2013 |
The Impact and Management of Subclinical Hypothyroidism for Improving Reproductive Outcomes such as Fertility and Miscarriage.
Topics: Abortion, Spontaneous; Biomarkers; Developmental Disabilities; Female; Fertility; Humans; Hypothyroi | 2016 |
Perinatal factors affecting thyroid hormone status in extreme preterm infants.
Topics: Brain; Developmental Disabilities; Female; Gestational Age; Humans; Hypothyroidism; Infant, Newborn; | 2008 |
Neuro-developmental deficits in early-treated congenital hypothyroidism.
Topics: Adolescent; Adult; Child; Child, Preschool; Congenital Hypothyroidism; Developmental Disabilities; H | 2008 |
Clinical importance of hypothyroxinemia in the preterm infant and a discussion of treatment concerns.
Topics: Cerebral Palsy; Cognition Disorders; Developmental Disabilities; Hormone Replacement Therapy; Humans | 2012 |
Neurodisability: metabolic and hormonal aspects.
Topics: Child; Developmental Disabilities; Female; Humans; Hypothyroidism; Iodine; Nervous System Diseases; | 2003 |
Hypothyroidism during pregnancy.
Topics: Adult; Breast Feeding; Developmental Disabilities; Drug Monitoring; Female; Humans; Hypothyroidism; | 2004 |
Prophylactic postnatal thyroid hormones for prevention of morbidity and mortality in preterm infants.
Topics: Developmental Disabilities; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; | 2007 |
Thyroid hormone and intellectual development: a clinician's view.
Topics: Brain; Congenital Hypothyroidism; Developmental Disabilities; Female; Humans; Infant, Newborn; Intel | 1999 |
Maternal hypothyroidism and child development. A review.
Topics: Brain; Child; Developmental Disabilities; Female; Humans; Hypothyroidism; Intellectual Disability; M | 1999 |
Thyroid hormone for preventing of neurodevelopmental impairment in preterm infants.
Topics: Developmental Disabilities; Humans; Infant, Newborn; Infant, Premature; Risk; Thyroxine | 2000 |
Thyroid disease in relation to pregnancy: a decade of change.
Topics: Abortion, Spontaneous; Autoantibodies; Autoimmune Diseases; Chorionic Gonadotropin; Developmental Di | 2000 |
The potential repercussions of maternal, fetal, and neonatal hypothyroxinemia on the progeny.
Topics: Developmental Disabilities; Embryonic and Fetal Development; Female; Fetal Diseases; Humans; Hypothy | 2000 |
Is neuropsychological development related to maternal hypothyroidism or to maternal hypothyroxinemia?
Topics: Animals; Child; Child Development; Child, Preschool; Developmental Disabilities; Female; Humans; Hyp | 2000 |
Treatment of congenital hypothyroidism.
Topics: Age Factors; Congenital Hypothyroidism; Developmental Disabilities; Drug Monitoring; Humans; Hypothy | 2001 |
Thyroid hormones for preventing neurodevelopmental impairment in preterm infants.
Topics: Developmental Disabilities; Humans; Infant, Newborn; Infant, Premature; Risk; Thyroxine | 2001 |
Another reason for iodine prophylaxis.
Topics: Adult; Child; Child, Preschool; Congenital Hypothyroidism; Developmental Disabilities; Female; Fetal | 1990 |
Treatment of growth hormone deficiency.
Topics: Body Height; Chorionic Gonadotropin; Developmental Disabilities; Drug Administration Schedule; Femal | 1986 |
9 trials available for thyroxine and Developmental Disabilities
| Article | Year |
|---|---|
Treatment of Subclinical Hypothyroidism or Hypothyroxinemia in Pregnancy.
Topics: Adult; Child, Preschool; Developmental Disabilities; Female; Follow-Up Studies; Humans; Hypothyroidi | 2017 |
TIPIT: a randomised controlled trial of thyroxine in preterm infants under 28 weeks gestation: magnetic resonance imaging and magnetic resonance angiography protocol.
Topics: Administration, Oral; Brain; Developmental Disabilities; Double-Blind Method; Gestational Age; Human | 2008 |
Cognition and behavior at school entry in children with congenital hypothyroidism treated early with high-dose levothyroxine.
Topics: Analysis of Variance; Child Behavior Disorders; Child, Preschool; Cognition; Congenital Hypothyroidi | 2004 |
Ten-year follow-up of children born at <30 weeks' gestational age supplemented with thyroxine in the neonatal period in a randomized, controlled trial.
Topics: Brain; Child; Child Behavior; Child Development; Child, Preschool; Developmental Disabilities; Doubl | 2005 |
Influence of timing and dose of thyroid hormone replacement on mental, psychomotor, and behavioral development in children with congenital hypothyroidism.
Topics: Attention Deficit and Disruptive Behavior Disorders; Child; Child Development; Child, Preschool; Con | 2005 |
Neurodevelopmental outcomes in congenital hypothyroidism: comparison of initial T4 dose and time to reach target T4 and TSH.
Topics: Analysis of Variance; Child; Child Behavior; Child Development; Child, Preschool; Congenital Hypothy | 2005 |
Effects of thyroxine supplementation on neurologic development in infants born at less than 30 weeks' gestation.
Topics: Central Nervous System; Child Development; Developmental Disabilities; Double-Blind Method; Female; | 1997 |
Thyroid function in preterm newborns; is T4 treatment required in infants < 27 weeks' gestational age?
Topics: Developmental Disabilities; Double-Blind Method; Gestational Age; Humans; Infant, Premature; Nervous | 1997 |
Neonatal thyroxine supplementation in very preterm children: developmental outcome evaluated at early school age.
Topics: Child; Child Development; Child, Preschool; Developmental Disabilities; Follow-Up Studies; Gestation | 2001 |
41 other studies available for thyroxine and Developmental Disabilities
| Article | Year |
|---|---|
General Movement assessment and neurodevelopmental trajectory in extremely preterm infants with hypothyroxinaemia of prematurity (THOP).
Topics: Child, Preschool; Developmental Disabilities; Female; Humans; Hypothyroidism; Infant; Infant, Extrem | 2020 |
Transient neonatal hyperthyrotropinemia is a risk factor for developing persistent hyperthyrotropinemia in childhood with repercussion on developmental status.
Topics: Age of Onset; Child; Child Development; Child, Preschool; Developmental Disabilities; Female; Humans | 2015 |
No Association Between Transient Hypothyroxinemia of Prematurity and Neurodevelopmental Outcome in Young Adulthood.
Topics: Cohort Studies; Congenital Hypothyroidism; Developmental Disabilities; Female; Follow-Up Studies; Hu | 2015 |
A typical presentations of hypothyroidism and associated problems in Ibadan, Nigeria.
Topics: Cyanosis; Delayed Diagnosis; Developmental Disabilities; Edema; Humans; Hypothyroidism; Infant; Male | 2015 |
Maternal thyroid hypofunction and pregnancy outcome.
Topics: Child; Developmental Disabilities; Female; Follow-Up Studies; Hormone Replacement Therapy; Humans; H | 2008 |
Impact of neonatal thyroid hormone insufficiency and medical morbidity on infant neurodevelopment and attention following preterm birth.
Topics: Attention Deficit Disorder with Hyperactivity; Child Development; Developmental Disabilities; Humans | 2009 |
Maternal isolated hypothyroxinemia: To treat or not to treat?
Topics: Child; Developmental Disabilities; Female; Humans; Hypothyroidism; Pregnancy; Pregnancy Complication | 2009 |
Role of late maternal thyroid hormones in cerebral cortex development: an experimental model for human prematurity.
Topics: Animals; Animals, Newborn; Body Patterning; Brain; Developmental Disabilities; Disease Models, Anima | 2010 |
Increasing supplemental thyroid hormone use among premature infants born at 23 to 32 weeks' gestation.
Topics: Child; Child, Preschool; Congenital Hypothyroidism; Developmental Disabilities; Hormone Replacement | 2010 |
Levels of neonatal thyroid hormone in preterm infants and neurodevelopmental outcome at 5 1/2 years: millennium cohort study.
Topics: Brain; Child Development; Child, Preschool; Cognition; Cohort Studies; Developmental Disabilities; F | 2010 |
Risk factors for neurodevelopmental deficits in congenital hypothyroidism after early substitution treatment.
Topics: Child Development; Child, Preschool; Congenital Hypothyroidism; Developmental Disabilities; Female; | 2011 |
Neurodevelopment in children born to hypothyroid mothers restored to normal thyroxine (T₄) concentration by late pregnancy in Japan: no apparent influence of maternal T₄ deficiency.
Topics: Adolescent; Child; Child Development; Child, Preschool; Developmental Disabilities; Female; Fetal De | 2012 |
Effect of maternal excessive iodine intake on neurodevelopment and cognitive function in rat offspring.
Topics: Age Factors; Animals; Animals, Newborn; Anti-Infective Agents, Local; Brain-Derived Neurotrophic Fac | 2012 |
Thyroxine levels during pregnancy in healthy women and early child neurodevelopment.
Topics: Adolescent; Adult; Biomarkers; Cognition Disorders; Cohort Studies; Developmental Disabilities; Fema | 2013 |
Visual diagnosis: two infants who have coarse facial features and growth and developmental delay.
Topics: Congenital Hypothyroidism; Developmental Disabilities; Facies; Growth Disorders; Humans; Hypothyroid | 2003 |
[Hypothyroidism in children. 82 cases].
Topics: Child; Developmental Disabilities; Female; Growth Disorders; Humans; Hypothyroidism; Infant, Newborn | 2002 |
[Frequency of subclinical hypothyroidism among healthy children and those with neurological conditions in the state of Mérida, Venezuela].
Topics: Autoantibodies; Child, Preschool; Comorbidity; Developmental Disabilities; Female; Humans; Hypothyro | 2003 |
In search of the optimal therapy for congenital hypothyroidism.
Topics: Cognition; Congenital Hypothyroidism; Developmental Disabilities; Dose-Response Relationship, Drug; | 2004 |
Severe hypothyroidism due to atrophic thyroiditis from second year of life influenced developmental outcome.
Topics: Atrophy; Biopsy, Needle; Child, Preschool; Developmental Disabilities; Dose-Response Relationship, D | 2005 |
Neonatal effects of maternal hypothyroxinemia during early pregnancy.
Topics: Child Development; Depression, Postpartum; Developmental Disabilities; Female; Humans; Hypothyroidis | 2006 |
Onset of acquired autoimmune hypothyroidism in infancy: a presentation of delayed gross-motor development and rhabdomyolysis.
Topics: Antibodies; Autoimmune Diseases; Creatine Kinase; Developmental Disabilities; Female; Hormone Replac | 2006 |
Analysis of physical and mental development of children with aplasia, hypoplasia and ectopy of the thyroid gland.
Topics: Adolescent; Body Height; Child; Child Development; Child, Preschool; Congenital Hypothyroidism; Deve | 2006 |
Unusual clinical presentation of primary hypothyroidism in a very young infant caused by autoimmune thyroiditis: case report and update of the literature.
Topics: Autoantibodies; Developmental Disabilities; Hormone Replacement Therapy; Humans; Hypothyroidism; Inf | 2007 |
A Japanese patient of congenital hypothyroidism with cerebellar atrophy.
Topics: Cerebellar Ataxia; Congenital Hypothyroidism; Developmental Disabilities; Humans; Infant, Newborn; M | 2007 |
Case report: consumptive hypothyroidism consequent to multiple infantile hepatic haemangiomas.
Topics: Developmental Disabilities; Glucocorticoids; Hemangioma; Humans; Hypothyroidism; Infant; Liver Neopl | 2008 |
[Physical and mental development of children with congenital hypothyroidism].
Topics: Age Determination by Skeleton; Anthropometry; Child; Child, Preschool; Congenital Hypothyroidism; De | 1993 |
Intellectual development at 10 years in early treated congenital hypothyroidism.
Topics: Child; Congenital Hypothyroidism; Developmental Disabilities; Female; Follow-Up Studies; Humans; Hyp | 1994 |
[Neonatal Basedow's disease in twins from a mother with severe T3 hyperthyroidism].
Topics: Adrenergic beta-Antagonists; Adult; Antithyroid Agents; Autoantibodies; Developmental Disabilities; | 1997 |
Does transient hypothyroxinemia cause abnormal neurodevelopment in premature infants?
Topics: Developmental Disabilities; Humans; Infant, Newborn; Infant, Premature; Neonatal Screening; Research | 1998 |
Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child.
Topics: Adult; Case-Control Studies; Child; Child Language; Developmental Disabilities; Female; Fetal Diseas | 1999 |
Should all pregnant women be screened for hypothyroidism?
Topics: Developmental Disabilities; Female; Humans; Hypothyroidism; Mass Screening; Pregnancy; Thyroxine | 1999 |
Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child.
Topics: Child; Developmental Disabilities; Female; Humans; Hypothyroidism; Intelligence; Pregnancy; Pregnanc | 1999 |
Congenital hypothyroidism: expanding the spectrum.
Topics: Adolescent; Case-Control Studies; Child; Congenital Hypothyroidism; Developmental Disabilities; Foll | 2000 |
Three-year follow-up of borderline congenital hypothyroidism.
Topics: Body Height; Body Weight; Child Development; Child, Preschool; Congenital Hypothyroidism; Developmen | 2000 |
Longterm outcome in children with congenital hypothyroidism.
Topics: Achievement; Adolescent; Child; Congenital Hypothyroidism; Developmental Disabilities; France; Human | 2001 |
Influence of severity of congenital hypothyroidism and adequacy of treatment on school achievement in young adolescents: a population-based cohort study.
Topics: Achievement; Adolescent; Age Factors; Case-Control Studies; Child; Congenital Hypothyroidism; Develo | 2001 |
Transient hypothyroxinaemia associated with developmental delay in very preterm infants.
Topics: Child, Preschool; Congenital Hypothyroidism; Developmental Disabilities; Follow-Up Studies; Humans; | 1992 |
[Psychomotor and intellectual development in 52 children with congenital hypothyroidism screened at birth. Factors likely to have an effect on prognosis].
Topics: Child; Child, Preschool; Congenital Hypothyroidism; Developmental Disabilities; Female; Humans; Hypo | 1990 |
[Comparative study of psychometric results of 2 french speaking populations with hypothyroidism detected at birth].
Topics: Bone Development; Child; Child, Preschool; Cohort Studies; Congenital Hypothyroidism; Developmental | 1990 |
Anticonvulsant medication use and circulating levels of total thyroxine, retinol binding protein, and vitamin A in children with delayed cognitive development.
Topics: Anticonvulsants; Child; Child, Preschool; Developmental Disabilities; Humans; Nutritional Status; Re | 1987 |
Congenital hypothyroidism in Singapore: prescreening era.
Topics: Child; Child, Preschool; Congenital Hypothyroidism; Developmental Disabilities; Female; Humans; Hypo | 1988 |